This case study describes a 35-year-old man who presented with end-stage AIDS and liver disease requiring possible liver transplantation. He had HIV for over 10 years, as well as hepatitis B and C. His CD4 count was 69 and viral load was over 100,000. He had severe ascites, high bilirubin, low albumin, and elevated INR. After starting antiretroviral therapy, his viral load decreased and CD4 increased, allowing him to undergo liver transplantation. He had an uneventful recovery and suppression of both HIV and HBV.
Crimson Publishers: Interferon-Free Therapy for Hepatits C in Brazil and Sust...CrimsonGastroenterology
Introduction: Hepatitis C has been treated with interferon and ribavirin for over a decade with described global sustained virological response rates of 33% to 56%. Direct acting antiviral drugs available since 2013 in USA and 2015 in Brazil are changing this reality.
Purpose: Analyze the real-life efficacy and safety of interferon-free therapy.
Methods: Repot six cases of different treatments guided by north-american and european guildelines.
Results: Every reported patient achieved sustained virological response. The only adverse event was anemia in one patient.
Conclusion: Direct-acting antiviral drugs will dramatically change the population which can be treated and increase sustained virological response rates.
Crimson Publishers: Interferon-Free Therapy for Hepatits C in Brazil and Sust...CrimsonGastroenterology
Introduction: Hepatitis C has been treated with interferon and ribavirin for over a decade with described global sustained virological response rates of 33% to 56%. Direct acting antiviral drugs available since 2013 in USA and 2015 in Brazil are changing this reality.
Purpose: Analyze the real-life efficacy and safety of interferon-free therapy.
Methods: Repot six cases of different treatments guided by north-american and european guildelines.
Results: Every reported patient achieved sustained virological response. The only adverse event was anemia in one patient.
Conclusion: Direct-acting antiviral drugs will dramatically change the population which can be treated and increase sustained virological response rates.
HIV Nursing and Home & Community Care Conference griehl
This joint presentation by Susann Nasewich and Greg Riehl will describe HIV Nursing as it relates to pre and post test counseling, and what is important to know for home and community care nurses and aides.
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...hivlifeinfo
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Contemporary Management of HIV. Managing HIV in Viral Hepatitis Coinfection.2016
In this downloadable slideset, David L. Wyles, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for ART management in patients with HIV and viral hepatitis coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 1.85 MB
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
All manuscripts are subject to rapid peer review. Those of high quality (not previously published and not under consideration for publication in another journal) will be published without delay.
This lecture is about Treatment of HCV Genotype 4 presented by Dr. Tamer Elbaz, Assistant professor of Hepatology & Gastroenterology, Cairo University.
The lecture was presented in the scientific meeting of Internal and Tropical Medicine departments, Ahmed Maher Teaching Hospital titled (Towards Eradication of HCV in Egypt) in celebration of World Hepatitis Day on July 28, 2016.
https://www.facebook.com/AMTH.IM
https://www.facebook.com/events/1072758396145209/
http://www.no4c.com
8. Child-Pugh Score Calculator Measure 1 point 2 points 3 points units Bilirubin <34 (<2) 34-50 (2-3) >50 (>3) μ mol/l (mg/dl) Albumin >35 28-35 <28 g/l INR <1.7 1.71-2.20 > 2.20 no unit Ascites None Mild Severe no unit Encephalopathy None Grade I-II (or suppressed with medication) Grade III-IV (or refractory) no unit
9.
10.
11.
12.
13.
14. Is HBsAg present? Is IgM anti-HBc present? Is HBeAg or HBV DNA present? Is anti-HBs present? Chronic Hepatitis Acute Hepatitis Replicative HBV infection Non-replicative HBV infection Recovered or vaccinated +/- anti-HBc No HBV infection No Yes Yes Yes Yes No No No Anti-HBc +/- no yes
15. Clinical Liver Disease and HBV Genotype Duong TN, et al. Journal of Medical Virology. 2004;72:551–557. Diagnosis, n (%) Genotypes N Asymptomatic carrier Chronic hepatitis Liver cirrhosis HCC Genotype A 11 8 (72.7) 3 (27.3) 0 0 Genotype B 14 10 (71.4) 3 (21.4) 0 1 (7.2) Genotype C 350 129 (36.8) 126 (36.0) 50 (14.3) 45 (12.9) Genotype D 38 32 (84.2) b 6 (15.8) a 0 0 a a P <0.05 vs genotype C. b P <0.001 vs genotype C.
16.
17.
18. Management Roadmap According to 24 Week Virologic Response Add another drug without cross resistance Monitor every 3 months Add another drug or Continue Monitor every 3 months Continue Monitor every 6 months Inadequate response >10 4 copies/mL Complete response <300 copies/mL Partial response 300-10 4 copies/mL Week 24: Early predictors of efficacy Keeffe et al. Clin Gastroenterol Hepatol, 2007
19.
20.
21.
22.
23.
24.
25.
26. ARTEMIS: Darunavir + Ritonavir Versus Lopinavir/Ritonavir Mills A, et al. 48 th ICAAC. Washington, DC, 2008. Abstract H-1250c. All patients received emtricitabine/tenofovir DF. Virologic failure: >50 copies/mL. * P =0.0437 versus lopinavir/r. † P <0.001 for non-inferiority to lopinavir/r. ‡ P =0.023 versus lopinavir/ritonavir. Week 96 Outcomes Darunavir + RTV (n=343) Lopinavir/r (n=346) Virologic failure (%) 12* 17 HIV RNA <50 copies/mL (%) 79 † 71 By baseline HIV RNA <100K copies/mL > 100K copies/mL 81 (n=226) 76 ‡ (n=117) 75 (n=226) 63 (n=120)
27. ARTEMIS: 96-Week Tolerability Results All patients received emtricitabine/tenofovir DF. * P <0.001 versus lopinavir/r. † P =0.0016 versus lopinavir/r. ‡ P <0.0001 versus lopinavir/ritonavir. Mills A, et al. 48 th ICAAC. Washington, DC, 2008. Abstract H-1250c. Darunavir + RTV (n=343) Lopinavir/r (n=346) Grade 2-4 adverse events Diarrhea Nausea Rash (all types) 4* 2 3 11 3 1 Grade 2-4 lipid abnormalities Total cholesterol LDL-C Triglycerides 18 † 18 4 ‡ 28 15 13
47. LIPIDS A5202: ATV/r vs. EFV Median Changes in Fasting Lipids (mg/dL) In low HIV RNA stratum, in comparison between ABC/3TC vs. TDF/FTC: significantly greater increase in TC, LDL, HDL with both EFV and ATV/r; greater increase in TG with ATV/r Median Change in Fasting Lipids (Week 48, mg/dL) Daar E, et al. 17th CROI; San Francisco, CA; February 16-19, 2010. Abst. 59LB. TC LDL HDL TG ABC/3TC ATV/r 29 13 8 24 EFV 40 21 12 15 P-value <0.001 0.002 <0.001 0.26 TDF/FTC ATV/r 10 2 5 14 EFV 22 10 8 13 P-value <0.001 0.002 <0.001 0.26